Published in Medicine and Law Weekly, July 1st, 2005
In the first agreement, ACT acquired an option to exclusively license cloning patents from TranXenoGen, Inc., of Shrewsbury, Massachusetts. The patents include U.S. patents 5,480,772; 5,651,992; 5,773,217; 6,245,567; 6,753,457; and 6,878,546. This patent family includes granted claims related to somatic cell nuclear transfer and the use of oocytes and oocyte extracts to reprogram somatic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly